Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,437Revenue $M778Net Margin (%)15.2Z-Score19.2
Enterprise Value $M2,272EPS $2.3Operating Margin %23.6F-Score5
P/E(ttm))23.6Cash Flow Per Share $1.4Pre-tax Margin (%)24.0Higher ROA y-yN
Price/Book3.610-y EBITDA Growth Rate %0Quick Ratio5.0Cash flow > EarningsY
Price/Sales3.65-y EBITDA Growth Rate %22.7Current Ratio5.4Lower Leverage y-yY
Price/Cash Flow19.2y-y EBITDA Growth Rate %-32.2ROA % (ttm)13.8Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)15.7Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M71.1ROI % (ttm)21.6Gross Margin Increase y-yN

Gurus Latest Trades with MYGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MYGNJoel Greenblatt 2014-12-31 Reduce-0.11%$32.01 - $39.49
($35.44)
$ 34.66-2%Reduce -34.58%568,865
MYGNKen Fisher 2014-12-31 Buy 0.01%$32.01 - $39.48
($35.39)
$ 34.66-2%New holding88,333
MYGNJoel Greenblatt 2014-09-30 Reduce-0.12%$35.44 - $40.41
($37.28)
$ 34.66-8%Reduce -22.18%869,531
MYGNJean-Marie Eveillard 2014-06-30 Sold Out -0.03%$33.1 - $42.21
($37.18)
$ 34.66-7%Sold Out0
MYGNThird Avenue Management 2014-03-31 Sold Out -0.13%$20.79 - $38.17
($30.6)
$ 34.6612%Sold Out0
MYGNJean-Marie Eveillard 2014-03-31 Buy 0.03%$20.79 - $38.17
($30.6)
$ 34.6612%New holding284,826
MYGNRonald Muhlenkamp 2013-12-31 Sold Out -2.3%$20.79 - $30.65
($25.36)
$ 34.6627%Sold Out0
MYGNJoel Greenblatt 2013-12-31 Add0.18%$20.79 - $30.65
($25.36)
$ 34.6627%Add 36.27%1,316,314
MYGNThird Avenue Management 2013-12-31 Buy 0.13%$20.79 - $30.65
($25.36)
$ 34.6627%New holding328,314
MYGNJoel Greenblatt 2013-09-30 Add0.32%$24.396 - $31.8
($28.51)
$ 34.6618%Add 74.78%965,987
MYGNRonald Muhlenkamp 2013-06-30 Buy 2.7%$24.35 - $34.26
($28.98)
$ 34.6616%New holding481,900
MYGNRon Baron 2013-06-30 Sold Out -0.09%$24.35 - $34.26
($28.98)
$ 34.6616%Sold Out0
MYGNJoel Greenblatt 2013-03-31 Add0.24%$24.19 - $27.68
($25.95)
$ 34.6625%Add 62.99%489,388
MYGNRon Baron 2013-03-31 Buy 0.09%$24.19 - $27.68
($25.95)
$ 34.6625%New holding658,653
MYGNJoel Greenblatt 2012-03-31 Add0.22%$20.36 - $25.64
($21.82)
$ 34.6637%Add 40.27%363,079
MYGNJoel Greenblatt 2011-12-31 Add0.11%$18.25 - $21.76
($20.37)
$ 34.6641%Add 21.40%258,844
MYGNJoel Greenblatt 2011-09-30 Add0.1%$17.86 - $23.86
($20.44)
$ 34.6641%Add 17.12%213,215
MYGNGeorge Soros 2011-09-30 Sold Out -0.0022%$17.86 - $23.86
($20.44)
$ 34.6641%Sold Out0
MYGNJoel Greenblatt 2011-06-30 Add0.24%$19.92 - $25.53
($22.77)
$ 34.6634%Add 70.62%182,045
MYGNGeorge Soros 2011-06-30 Buy $19.92 - $25.53
($22.77)
$ 34.6634%New holding6,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MYGN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


MYGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
King Gary A.Exec. VP International Ops 2014-11-03Sell6,568$39.95-13.72view
Evans James SCFO 2014-09-30Sell21,850$38.99-11.59view
Evans James SCFO 2014-09-24Sell8,790$37.98-9.24view
Evans James SCFO 2014-09-23Sell110,463$37.89-9.03view
LANCHBURY JERRY SChief Scientific Officer 2014-07-14Sell20,000$39.85-13.5view
MELDRUM PETER DPresident & C.E.O. 2014-07-14Sell24,000$39.5-12.73view
HENDERSON JOHN TDirector 2014-06-05Sell5,000$35.7-3.45view
Rogers Ronald S.Exec VP Corp Communications 2014-05-09Sell12,500$36.01-4.28view
MARSH RICHARD ME.V.P., General Counsel 2014-04-30Sell30,000$41.8-17.54view
MARSH RICHARD ME.V.P., General Counsel 2014-04-23Sell31,516$39.8-13.39view

Press Releases about MYGN :

    Quarterly/Annual Reports about MYGN:

    News about MYGN:

    Articles On GuruFocus.com
    Chuck Royce Comments on Myriad Genetics Oct 08 2014 
    Chuck Royce’s Royce Premier Fund Second Quarter 2014 Manager Commentary Oct 08 2014 
    Why I Bought Myriad Genetics (MYGN) Apr 28 2014 
    Scott Black, Delphi Management Recommends Stocks Nov 19 2013 
    Surfing for Billionaire Bargains Sep 23 2013 
    Baron Funds Comments on Myriad Genetics Inc. Jun 06 2013 
    RS Investments' Value Fund First Quarter 2012 Mutual Fund Commentary Apr 17 2012 
    Chuck Royce Buys Hawkins Inc., Myriad Genetics, and Fairchild Semiconductor Jul 07 2011 
    Myriad Genetics Inc. Reports Operating Results (10-Q) May 05 2010 
    Myriad Genetics Inc. (MYGN) CFO James S Evans sells 8,400 Shares Mar 12 2010 

    More From Other Websites
    Cowen Thinks 3 Life Science Stocks Can Beat Earnings Estimates Apr 09 2015
    Myriad and AstraZeneca Expand Research Collaboration on Lynparza Apr 01 2015
    Myriad and AstraZeneca Expand Research Collaboration on Lynparza Apr 01 2015
    Goldman Sachs Cuts Myriad Genetics To Sell, Ups Alere Mar 26 2015
    Myriad Poised on Portfolio Strength Despite Y/Y Downfall in Q2 - Analyst Blog Mar 23 2015
    Myriad Announces Prolaris(R) Test Biopsy Results From EMPATHY-P Study at European Association of... Mar 20 2015
    Myriad Announces Prolaris(R) Test Biopsy Results From EMPATHY-P Study at European Association of... Mar 20 2015
    Myriad and BioMarin Expand Collaboration to Evaluate myChoice HRD(TM) as a Companion Diagnostic for... Mar 17 2015
    Myriad and BioMarin Expand Collaboration to Evaluate myChoice HRD(TM) as a Companion Diagnostic for... Mar 17 2015
    Coverage initiated on Myriad Genetics by UBS Mar 10 2015
    Myriad Genetics Unveils Simoa-based Immunoassay Services - Analyst Blog Mar 09 2015
    Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa(TM) Platform Mar 05 2015
    Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa(TM) Platform Mar 05 2015
    Myriad Publishes myPath(TM) Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology Mar 04 2015
    Myriad Publishes myPath(TM) Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology Mar 04 2015
    Myriad Genetics to Present at the Barclays Global Healthcare Conference Mar 03 2015
    Myriad Genetics to Present at the Barclays Global Healthcare Conference Mar 02 2015
    What Falling Estimates & Price Mean for Myriad Genetics (MYGN) - Tale of the Tape Mar 02 2015
    Myriad Board Approves $200 Million Increase in Share Repurchase Program Feb 25 2015
    MYRIAD GENETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 24 2015
    Iridian bumps up position in Myriad Genetics Feb 17 2015
    GeneDx, Inc. and its Parent BioReference Labs Announce Settlement of Their Cancer Gene Testing... Feb 17 2015
    MYRIAD GENETICS INC Financials Feb 10 2015
    Quest, Myriad Settle Patent Dispute on Breast Cancer Tests Feb 09 2015
    Quest Diagnostics and Myriad Genetics End BRCA Patent Litigation Feb 09 2015
    10-Q for Myriad Genetics, Inc. Feb 06 2015
    Myriad Genetics to Present at the 2015 Leerink Global Healthcare Conference Feb 06 2015
    Myriad Genetics to Present at the 2015 Leerink Global Healthcare Conference Feb 06 2015
    Myriad Genetics (MYGN) Stock Tumbling Today After Jefferies Price Target Reduction Feb 04 2015
    Myriad Genetics Sinks 10% On Lowered Guidance, CEO Retirement Feb 04 2015
    JMP Securities Upgrades Myriad Genetics, Says 'Revised Guidance Lowers The Bar' Feb 04 2015
    Ahead of the Bell: Myriad sinks after cutting 2015 forecast Feb 04 2015
    Myriad beats Street 2Q forecasts Feb 03 2015
    PDF 11.70 KB Feb 02 2015
    Myriad Genetics Names Johnathan M. Lancaster as Vice President of Medical Affairs Jan 22 2015
    Myriad RBM Joins Institut Pasteur in the Global Fight Against Tuberculosis Jan 20 2015
    Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion... Jan 08 2015
    Myriad Genetics to Present at the 2015 J.P. Morgan Annual Healthcare Conference Jan 05 2015
    Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience Dec 22 2014
    Myriad Receives FDA Approval of BRACAnalysis CDx(TM) as Companion Diagnostic for Lynparza(TM)... Dec 19 2014
    Three New Myriad Studies Highlighted at 2014 San Antonio Breast Cancer Symposium Dec 09 2014
    Myriad to Present Eight Studies at 2014 San Antonio Breast Cancer Symposium Dec 03 2014
    Study Shows Prolaris(R) Could Save Healthcare System $6 Billion Over 10 Years Dec 02 2014
    TESARO and Myriad Announce Companion Diagnostics Collaboration Nov 20 2014
    Myriad misses Street 1Q forecasts Nov 04 2014
    MARKET PULSE-MannKind, Rubicon, Liquidity Services, Acceleron, gold stocks Apr 02 2014
    Profit-taking drags Wall Street lower Mar 11 2014
    Biotech industry worries over US court's DNA ruling Jun 13 2013
    US stocks surge, dismissing Japan's plunge Jun 13 2013

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Antoniy
    ReplyAntoniy - 1 year ago
    hs
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK